Daiichi Sankyo Company, Limited

Equities

4568

JP3475350009

Market Closed - Japan Exchange Other stock markets 06:30:00 10/02/2026 GMT			5-day change	1st Jan Change
2,983.50 ^JPY	+1.07%		+2.30%	-10.89%

02-04	Daiichi Sankyo Announces First Patient Has Been Dosed in A First-In-Human Phase 1/2 Trial	CI
02-03	AstraZeneca says FDA backs Datroway, seeks more assurance on Saphnelo	AN

Transcript : Daiichi Sankyo Company, Limited - Special Call

Published on 12/16/2024 at 10:30 pm GMT

S&P Capital IQ

Presenter Speech
Kentaro Asakura (Executives)

Thank you for waiting, everybody. We'll now start Daiichi Sankyo's Science and Technology Day 2024. This is Ken Asakura from Corporate Communications, and

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Daiichi Sankyo Company, Limited

02-04	Daiichi Sankyo Announces First Patient Has Been Dosed in A First-In-Human Phase 1/2 Trial	CI
02-03	AstraZeneca says FDA backs Datroway, seeks more assurance on Saphnelo	AN
02-03	AstraZeneca Says Breast Cancer Treatment Granted US FDA Priority Review	MT
02-03	Daiichi Sankyo And AstraZeneca Receive Priority Review For DATROWAY For Treatment Of Unresectable Or Metastatic Triple Negative Breast Cancer In The U.S	CI
02-03	AG Barr adds drink brands; Filtronic profit falls	AN
02-03	AstraZeneca, Daiichi Sankyo's Breast Cancer Treatment Wins US Priority Review Status	MT
02-02	Nikkei slides on tech, resources sell-off despite weaker yen	RE
01-30	Daiichi Sankyo Company, Limited, Q3 2026 Earnings Call, Jan 30, 2026
01-30	Daiichi Sankyo's Nine-Month Profit Rises 4%	MT
01-30	Daiichi Sankyo Company, Limited Reports Earnings Results for the Nine Months Ended December 31, 2025	CI
01-28	Berenberg Ups AstraZeneca Price Target on Datroway's Sales Potential in Lung Cancer	MT
01-22	Daiichi and AstraZeneca's Enhertu wins sixth approval in China	AN
01-22	Daiichi Sankyo Appoints Veronika Rozehnal, Ph.D., as Head of Translational Research Center Europe	CI
01-21	National Medical Products Administration Approves Enhertu in China as the First and Only Her2 Directed Dc for the Second-Line Treatment of Patients with Her2 Positive Metastatic Gastric Cancer	CI
01-20	European Stocks Close Lower in Tuesday Trading; UK Unemployment Rises to 5.1%	MT
01-20	AstraZeneca, Daiichi Sankyo Say European Medicines Agency Validates Enhertu Application for Breast Cancer	MT
01-19	Daiichi Sankyo and AstraZeneca cheer EU milestone for cancer drug	AN
01-19	European Medicines Agency Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer	CI
01-13	TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer	CI
01-12	Daiichi Sankyo Company, Limited Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 01:30 PM
01-07	Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for Nanflyta®? Commercialization in Central and Eastern Europe	CI
01-05	Tranche Update on Daiichi Sankyo Company, Limited's Equity Buyback Plan announced on April 25, 2025.	CI
01-02	Daiichi Sankyo to spend roughly 300 billion yen to set up production facilities for targeted cancer medicine, Nikkei reports	RE
12-29	Cardiogeni swings to loss as Daiichi Sankyo deal drops away	AN
12-28	Senhwa?s CX-5461 with Astrazeneca/Daiichi Sankyo?s ADC, Trastuzumab Deruxtecan in Phase 1b HER2+ and Breast Cancer Trial; NCI Submits FDA Application	CI